PE20240657A1 - Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos - Google Patents
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicosInfo
- Publication number
- PE20240657A1 PE20240657A1 PE2023003180A PE2023003180A PE20240657A1 PE 20240657 A1 PE20240657 A1 PE 20240657A1 PE 2023003180 A PE2023003180 A PE 2023003180A PE 2023003180 A PE2023003180 A PE 2023003180A PE 20240657 A1 PE20240657 A1 PE 20240657A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- oxoisoindolin
- dione
- piperidine
- hemoglobinopathies
- Prior art date
Links
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 abstract 1
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a compuestos derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona de formula I', o una de sus sales, hidratos, solvatos, profarmacos, estereoisomeros o tautomeros farmaceuticamente aceptables, donde: cada R1 se selecciona de manera independiente de H, C1-C6alquilo, hidroxilo, entre otros; R2 se selecciona de H, C3-C11cicloalquilo, heterociclilo de 4 a 11 miembros que comprende 1-2 heteroatomos seleccionados de manera independiente de N, O, y S, C1-C6haloalquilo, entre otros; n es 0, 1, 2, 3, 4 o 5; y m es 0, 1 o 2. Estos compuestos reducen los niveles de expresion de proteinas que contiene de dedos de zinc ampliamente interespaciados (WIZ), o para inducir la expresion de la hemoglobina fetal (HbF). Tambien se refiere a la preparacion de dichos compuestos, sus compuestos intermedios, una composicion farmaceutica que comprende dichos compuestos y su uso en el tratamiento de trastornos sanguineos hereditarios, como hemoglobinopatias, beta-hemoglobinopatias, enfermedad de celulas falciformes y beta-talasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196422P | 2021-06-03 | 2021-06-03 | |
| PCT/IB2022/055131 WO2022254362A1 (en) | 2021-06-03 | 2022-06-01 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240657A1 true PE20240657A1 (es) | 2024-04-04 |
Family
ID=82115547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003180A PE20240657A1 (es) | 2021-06-03 | 2022-06-01 | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230019617A1 (es) |
| EP (1) | EP4347580A1 (es) |
| JP (1) | JP2024520654A (es) |
| KR (1) | KR20240013812A (es) |
| CN (1) | CN117062811A (es) |
| AR (1) | AR126052A1 (es) |
| AU (1) | AU2022284366A1 (es) |
| BR (1) | BR112023024905A2 (es) |
| CA (1) | CA3215410A1 (es) |
| CO (1) | CO2024000013A2 (es) |
| CR (1) | CR20230614A (es) |
| DO (1) | DOP2023000261A (es) |
| EC (1) | ECSP24000004A (es) |
| IL (1) | IL308094A (es) |
| MX (1) | MX2023014327A (es) |
| PE (1) | PE20240657A1 (es) |
| TW (1) | TW202306570A (es) |
| WO (1) | WO2022254362A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3237577A1 (en) * | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2013543009A (ja) | 2010-11-18 | 2013-11-28 | デューテリア ファーマシューティカルズ， インコーポレイテッド | ３−ジュウテロ−ポマリドマイド |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| LT3689868T (lt) * | 2016-12-01 | 2023-12-27 | Arvinas Operations, Inc. | Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai |
| WO2020012334A1 (en) * | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| US20220177443A1 (en) * | 2018-12-03 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| JP2022552006A (ja) * | 2019-10-17 | 2022-12-14 | アルヴィナス・オペレーションズ・インコーポレイテッド | Ｂｃｌ６標的化部分に連結されたｅ３ユビキチンリガーゼ結合部分を含有する二官能性分子 |
| AU2020410514A1 (en) * | 2019-12-18 | 2022-06-30 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2022
- 2022-06-01 JP JP2023574412A patent/JP2024520654A/ja active Pending
- 2022-06-01 US US17/829,933 patent/US20230019617A1/en active Pending
- 2022-06-01 IL IL308094A patent/IL308094A/en unknown
- 2022-06-01 BR BR112023024905A patent/BR112023024905A2/pt unknown
- 2022-06-01 AR ARP220101454A patent/AR126052A1/es unknown
- 2022-06-01 KR KR1020237045016A patent/KR20240013812A/ko active Search and Examination
- 2022-06-01 CA CA3215410A patent/CA3215410A1/en active Pending
- 2022-06-01 WO PCT/IB2022/055131 patent/WO2022254362A1/en active Application Filing
- 2022-06-01 EP EP22731823.5A patent/EP4347580A1/en active Pending
- 2022-06-01 PE PE2023003180A patent/PE20240657A1/es unknown
- 2022-06-01 CR CR20230614A patent/CR20230614A/es unknown
- 2022-06-01 TW TW111120484A patent/TW202306570A/zh unknown
- 2022-06-01 CN CN202280022964.9A patent/CN117062811A/zh active Pending
- 2022-06-01 MX MX2023014327A patent/MX2023014327A/es unknown
- 2022-06-01 AU AU2022284366A patent/AU2022284366A1/en active Pending
-
2023
- 2023-11-29 DO DO2023000261A patent/DOP2023000261A/es unknown
-
2024
- 2024-01-02 CO CONC2024/0000013A patent/CO2024000013A2/es unknown
- 2024-01-02 EC ECSENADI20244A patent/ECSP24000004A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014327A (es) | 2023-12-13 |
| BR112023024905A2 (pt) | 2024-02-20 |
| WO2022254362A1 (en) | 2022-12-08 |
| AU2022284366A1 (en) | 2023-10-26 |
| KR20240013812A (ko) | 2024-01-30 |
| ECSP24000004A (es) | 2024-02-29 |
| CR20230614A (es) | 2024-02-01 |
| DOP2023000261A (es) | 2023-12-29 |
| CN117062811A (zh) | 2023-11-14 |
| JP2024520654A (ja) | 2024-05-24 |
| AR126052A1 (es) | 2023-09-06 |
| TW202306570A (zh) | 2023-02-16 |
| CA3215410A1 (en) | 2022-12-08 |
| IL308094A (en) | 2023-12-01 |
| US20230019617A1 (en) | 2023-01-19 |
| CO2024000013A2 (es) | 2024-01-25 |
| EP4347580A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240657A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos | |
| DOP2000000114A (es) | Oxazolidinonas substituidas y su uso | |
| UY28578A1 (es) | Derivados de amida | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| ES2616089T3 (es) | Composición cosmética | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| NO20092764L (no) | Isosorbid mononitrat derivater for behandling av okular hypertensjon | |
| ES2508591T3 (es) | Agente para suprimir la formación de células de la piel anormales causada por la exposición a la luz | |
| ES2129448T3 (es) | Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas. | |
| BR9706891A (pt) | Composto, medicamento, composição farmacêutica e composição cosmética. | |
| ECSP055673A (es) | Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| AR046665A1 (es) | Formulaciones orales de desoxipeganina y sus usos | |
| ES2058129T3 (es) | Composiciones farmaceuticas que comprenden una solucion acuosa de un derivado de piranoquinolina. | |
| BR0114339A (pt) | Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| ES2242075T3 (es) | Composicion topica que contiene brucina y utilizacion para el tratamiento de la piel dañada de un mamifero. | |
| JP6853547B2 (ja) | コラーゲン分解阻害用組成物 | |
| AR004402A1 (es) | Sulfonas ciclicas, procedimiento para prepararlas, preparaciones farmaceuticas que las contienen y empleo de las mismas para combatir enfermedades. | |
| BRPI0410664A (pt) | derivados de benzopirano substituìdos com um derivado de tioxobenzoxazole, sais farmaceuticamente aceitáveis destes, suas preparações e composições farmacêuticas contendo os mesmos |